|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||60.04 - 60.04|
|52-week range||60.04 - 60.04|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
It's been a good week for Novo Nordisk A/S (CPH:NOVO B) shareholders, because the company has just released its latest...
Britain's brightest and best drug researchers are packing their bags as clinical trials start to dwindle, leaving a nation renowned as a global leader in pharmaceutical development to face a future in the slow lane. This is a worst-case scenario outlined by some scientists and industry experts in the wake of Brexit, which they say could deprive the country of its role as Europe's leader in early-stage drug research, designing and hosting pan-EU trials. Pamela Kearns, professor of paediatric oncology at the University of Birmingham, worries that over time Britain will in particular lose out in the field of medicines that treat rare diseases and childhood cancers, where trials often need to collaborate and recruit across Europe to find enough patients.
Is Novo Nordisk A/S (CPH:NOVO B) a good dividend stock? How can we tell? Dividend paying companies with growing...
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns (1.4 billion pounds) based on trading of Novo shares for two years from February 2015.
Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline. The Danish company is pinning its hopes on a relatively new treatment for type 2 diabetes as its older insulin drugs face political pressure over the soaring cost of the life-sustaining medicine in the United States. Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns ($345 million) in the second quarter, which was higher than expected by analysts, sending shares in the world's top diabetes drugmaker 1.4% higher in early trading on Friday.
European shares slid on Friday with Italian stocks 2.5% lower on political uncertainty, while comments by U.S. President Donald Trump that he was not going to make a trade deal with China also weighed on sentiment. Italy's main index touched a two month low with its bank index tumbling 4.5% after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday and called for fresh elections.